◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

SBI Life Insurance Company Limited (SBILIFE) Revenue 2022–2026

Name: SBI Life Insurance Company Limited (SBILIFE) revenue history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

SBI Life Insurance Company Limited annual revenue for fiscal 2026 was ₹1.10 trillion, a decrease of 4.3% from ₹1.15 trillion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

SBILIFE Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹1.10T	₹1.15T	₹1.31T	₹806.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SBILIFE Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	₹463.5B	₹40.9B	₹461.1B	₹390.1B	₹230.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

8750 Revenue — Daiichi Life Group, Inc.
LICI Revenue — Life Insurance Corporation of India
8795 Revenue — T&D Holdings, Inc.
7181 Revenue — Japan Post Insurance Co., Ltd.
HDFCLIFE Revenue — HDFC Life Insurance Company Limited
8729 Revenue — Sony Financial Group Inc.

More SBILIFE metrics: Net Income · EPS · Free Cash Flow

All SBILIFE financial statements → Interactive SBILIFE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.